Fulcrum Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.77 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 287.64M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, ...